Research focuses on determining the effect of alternate dosing schedules and developing targeted nanomedicines to improve detection of disease and improve drug delivery and antitumor efficacy. Molecular pharmaceutics, quantitative analysis (LC-MS/MS), pharmacokinetic (PK) and pharmacodynamic (PD) principles are used to gain mechanistic insights into drug action, toxicity and delivery of lipid- and composite-nanomedicines. In vitro and in vivo models of human disease and in silico computational PK/PD modeling and simulations are used.
